Anastasia Ivanova

Generating author description...

All published works

Action	Title	Year	Authors
+	Isotonic Estimation of Additive Covariate Effects Under Proportional Hazard Models	2024	Yunro Chung Anastasia Ivanova Jason P. Fine
+	Pooling controls from nested case–control studies with the proportional risks model	2024	Yen Chung Chang Anastasia Ivanova Demetrius Albanes Jason P. Fine Yei Eun Shin
+ PDF Chat	Isotonic design for single-arm biomarker stratified trials	2024	Lang Li Anastasia Ivanova
+	Finding the best subgroup with differential treatment effect with multiple outcomes	2024	Beibo Zhao Jason P. Fine Anastasia Ivanova
+ PDF Chat	Isotonic design for single-arm biomarker stratified trials	2024	Lang Li Anastasia Ivanova
+	Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial	2024	Lang Li Anastasia Ivanova
+	Shape restricted additive hazards models: Monotone, unimodal, and U‐shape hazard functions	2024	Yunro Chung Anastasia Ivanova Jason P. Fine
+	A frequentist design for basket trials using adaptive lasso	2023	Lauren G. Kanapka Anastasia Ivanova
+	Covariate-Adaptive Biased Coin Randomization for Master Protocols with Multiple Interventions and Biomarker-Stratified Allocation	2023	Tianhao Song Lisa M. LaVange Anastasia Ivanova
+	Fully order restricted multi‐arm multi‐stage clinical trial design	2023	Lauren G. Kanapka Anastasia Ivanova
+ PDF Chat	Inference on subgroups identified based on a heterogeneous treatment effect in a post hoc analysis of a clinical trial	2023	Beibo Zhao Anastasia Ivanova Jason P. Fine
+	<scp>CRM</scp> and partial order <scp>CRM</scp> with adaptive rescaling for dose‐finding in immunotherapy trials with a continuous outcome	2023	Pooja T. Saha Jason P. Fine Anastasia Ivanova
+	A Challenge in Reweighting Data with Bilevel Optimization	2023	Anastasia Ivanova Pierre Ablin
+ PDF Chat	Impact of COVID-19 on the Russian Labor Market: Comparative Analysis of the Physical and Informational Spread of the Coronavirus	2022	Dmitriy Rodionov Anastasia Ivanova Olga Konnikova Evgenii Konnikov
+	Randomization tests in clinical trials with multiple imputation for handling missing data	2022	Anastasia Ivanova Seth Lederman Philip B. Stark Gregory M. Sullivan Ben Vaughn
+ PDF Chat	The properties of entropy as a measure of randomness in a clinical trial	2021	Steven Hoberman Anastasia Ivanova
+	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment	2021	Elliot Israel Loren C. Denlinger Leonard B. Bacharier Lisa M. LaVange Wendy C. Moore Michael C. Peters Steve N. Georas Rosalind J. Wright David T. Mauger Patricia Noël
+	Consistency of the <scp>CRM</scp> when the <scp>dose‐toxicity</scp> curve is not monotone and its application to the <scp>POCRM</scp>	2021	Pooja T. Saha Jason P. Fine Anastasia Ivanova
+	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment	2021	Elliot Israel Loren C. Denlinger Leonard B. Bacharier Lisa M. LaVange Wendy C. Moore Michael C. Peters Steve N. Georas Rosalind J. Wright David T. Mauger Patricia Noël
+ PDF Chat	Multi-stage adaptive enrichment trial design with subgroup estimation	2020	Neha Joshi Crystal Nguyen Anastasia Ivanova
+	Power calculations for the sequential parallel comparison design with continuous outcomes	2020	Anastasia Ivanova Bahjat F. Qaqish
+ PDF Chat	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations	2020	Anastasia Ivanova Elliot Israel Lisa M. LaVange Michael C. Peters Loren C. Denlinger Wendy C. Moore Leonard B. Bacharier Miriam Marquis Nathan Gotman Michael R. Kosorok
+ PDF Chat	Guest editors’note on the special issue <i>innovative design and analysis of complex clinical trials</i>	2020	Anastasia Ivanova Yuan Ji
+ PDF Chat	Continual reassessment method with regularization in phase I clinical trials	2020	Xiang Li Anastasia Ivanova Hong Tian Pilar Lim Kevin Liu
+ PDF Chat	Futility stopping in clinical trials, optimality and practical considerations	2020	Yen Chung Chang Tianhao Song Jane Monaco Anastasia Ivanova
+	Methods for clarifying criteria for study continuation at interim analysis	2020	Laura Elizabeth Wiener Anastasia Ivanova Gary G. Koch
+ PDF Chat	Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker	2019	Neha Joshi Jason P. Fine Rong Chu Anastasia Ivanova
+	Randomization-based analysis of covariance for inference in the sequential parallel comparison design	2019	Laura E. Wiener Anastasia Ivanova Siying Li Rachel Kloss Silverman Gary G. Koch
+ PDF Chat	Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups	2019	Xiaoqiang Xue Matthew C. Foster Anastasia Ivanova
+ PDF Chat	CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method	2019	Mohamed Amine Bayar Anastasia Ivanova Gwénaël Le Teuff
+ PDF Chat	Permutation and Bootstrap Testing for the Sequential Parallel Comparison Design	2019	Rachel Kloss Silverman Jason P. Fine Richard C. Zink Anastasia Ivanova
+	Safety Monitoring and Analysis in Oncology Trials	2018	Anastasia Ivanova Qi Jiang Olga Marchenko Richard C. Zink
+	Clinical Trial Designs with Prospective Patient Population Enrichment by Response	2018	Anastasia Ivanova Marc DeSomer Jürgen Hummel
+	Response-Adaptive Designs	2018	Feifang Hu Anastasia Ivanova
+	Sequential parallel comparison design with binary and time‐to‐event outcomes	2018	Rachel Kloss Silverman Anastasia Ivanova Jason P. Fine
+ PDF Chat	Partial likelihood estimation of isotonic proportional hazards models	2017	Yunro Chung Anastasia Ivanova Michael G. Hudgens Jason P. Fine
+ PDF Chat	Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?	2017	Tom Parke Olga Marchenko Vladimir V. Anisimov Anastasia Ivanova Christopher Jennison Inna Perevozskaya Guochen Song
+ PDF Chat	Selection of the initial design for the two-stage continual reassessment method	2017	Xiaoyu Jia Anastasia Ivanova Shing M. Lee
+ PDF Chat	Dose-finding designs for trials of molecularly targeted agents and immunotherapies	2017	Codruța Chiuzan Jonathan Shtaynberger Gulam A. Manji Jimmy Duong Gary K. Schwartz Anastasia Ivanova Shing M. Lee
+	Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design	2017	Rachel Kloss Silverman Anastasia Ivanova
+	Special Issue of Journal of Biopharmaceutical Statistics dedicated to 2016 Trends and Innovations in Clinical Trial Statistics (TICTS) Conference	2016	Marie Davidian Anastasia Ivanova Olga Marchenko
+	Adaptive designs for phase I trials 2	2016	Anastasia Ivanova
+	Adaptive designs for phase I trials 1	2016	Anastasia Ivanova
+ PDF Chat	The rapid enrollment design for Phase I clinical trials	2016	Anastasia Ivanova Yunfei Wang Matthew C. Foster
+	A BIRTH AND DEATH URN FOR RANDOMIZED CLINICAL TRIALS: ASYMPTOTIC METHODS	2016	Anastasia Ivanova William F. Rosenberger S. D. Durham Nancy Flournoy
+ PDF Chat	Practical designs for Phase I combination studies in oncology	2016	Nolan A. Wages Anastasia Ivanova Olga Marchenko
+ PDF Chat	The rapid enrollment design for Phase I clinical trials: The Rapid Enrollment Design for Phase I Clinical Trials	2016	Anastasia Ivanova Yunfei Wang Matthew C. Foster
+ PDF Chat	Two-stage design for phase II oncology trials with relaxed futility stopping	2015	Anastasia Ivanova Allison M. Deal
+ PDF Chat	Comment	2015	Anastasia Ivanova Keaven M. Anderson Gary L. Rosner Eric H. Rubin
+ PDF Chat	Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials	2015	Guochen Song Anastasia Ivanova
+ PDF Chat	Practical designs for Phase I combination studies in oncology	2015	Nolan A. Wages Anastasia Ivanova Olga Marchenko
+	Can sequential parallel comparison design and two-way enriched design be useful in medical device clinical trials?	2015	Anastasia Ivanova Zhiwei Zhang Laura Thompson Ying Yang Richard M. Kotz Xin Fang
+ PDF Chat	Nine-year change in statistical design, profile, and success rates of Phase II oncology trials	2015	Anastasia Ivanova Barry Paul Olga Marchenko Guochen Song Neerali Patel Stergios J. Moschos
+	Monitoring rules for toxicity in Phase II oncology trials	2015	Anastasia Ivanova Guochen Song Olga Marchenko Stergios J. Moschos
+ PDF Chat	Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials	2015	Guochen Song Anastasia Ivanova
+ PDF Chat	Higher order response-adaptive urn designs for clinical trials with highly successful treatments	2015	Anastasia Ivanova Steven Hoberman
+	Dose finding with continuous outcome in phase I oncology trials	2014	Yunfei Wang Anastasia Ivanova
+	Dose Escalation and Up‐and‐Down Designs	2014	Anastasia Ivanova
+	Phase <scp>I</scp> Trials in Oncology	2014	Anastasia Ivanova
+	Up‐and‐Down and Escalation Designs	2014	Anastasia Ivanova Assaf P. Oron
+	Phase I Trials in Oncology	2014	Anastasia Ivanova
+	Dose Finding With the Sequential Parallel Comparison Design	2014	Jessie J. Wang Anastasia Ivanova
+ PDF Chat	Higher Order Response-Adaptive Urn Designs for Clinical Trials with Highly Successful Treatments	2014	Anastasia Ivanova Steven Hoberman
+ PDF Chat	Linear Mixed Effects Models under Inequality Constraints with Applications	2014	Laura Farnan Anastasia Ivanova Shyamal D. Peddada
+ PDF Chat	Advances in Statistical Approaches to Oncology Drug Development	2014	Anastasia Ivanova Gary L. Rosner Olga Marchenko Tom Parke Inna Perevozskaya Yanping Wang
+	Advances in Statistical Approaches to Oncology Drug Development	2013	Anastasia Ivanova Gary L. Rosner Olga Marchenko Tom Parke Inna Perevozskaya Yanping Wang
+	When should the sequential parallel comparison design be used in clinical trials?	2013	Lee Baer Anastasia Ivanova
+ PDF Chat	Dose finding when the target dose is on a plateau of a dose–response curve: comparison of fully sequential designs	2013	Anastasia Ivanova Changfu Xiao
+	Letter to the Editor	2013	Anastasia Ivanova Roy Tamura
+ PDF Chat	Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs	2013	Anastasia Ivanova Changfu Xiao
+ PDF Chat	Two‐stage designs for Phase 2 dose‐finding trials	2012	Anastasia Ivanova Changfu Xiao Yevgen Tymofyeyev
+ PDF Chat	Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates	2012	Changfu Xiao Anastasia Ivanova
+ PDF Chat	Efficient designs for phase II oncology trials with ordinal outcome	2012	Anastasia Ivanova Jane Monaco Thomas E. Stinchcombe
+ PDF Chat	Two-stage designs for Phase 2 dose-finding trials	2012	Anastasia Ivanova Changfu Xiao Yevgen Tymofyeyev
+	A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal	2011	Anastasia Ivanova Roy Tamura
+	Optimality, sample size, and power calculations for the sequential parallel comparison design	2011	Anastasia Ivanova Bahjat F. Qaqish David Schoenfeld
+ PDF Chat	Addendum to ‘An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study’	2010	Anastasia Ivanova Kenneth Liu Ellen Snyder Duane Snavely
+ PDF Chat	An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose‐finding study	2009	Anastasia Ivanova Ken Liu Ellen Snyder Duane Snavely
+	An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations	2009	Anastasia Ivanova Michael Murphy
+ PDF Chat	Comparison of Isotonic Designs for Dose-Finding	2009	Anastasia Ivanova Nancy Flournoy
+ PDF Chat	Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach	2009	Anastasia Ivanova Se Hee Kim
+ PDF Chat	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist	2008	Sarah Zohar Lian Qing Vincent Lévy Ken Cheung Anastasia Ivanova Sylvie Chevret
+ PDF Chat	Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach	2008	Anastasia Ivanova Se Hee Kim
+ PDF Chat	Adaptive dose finding based on <i>t</i>‐statistic for dose–response trials	2008	Anastasia Ivanova James A. Bolognese Inna Perevozskaya
+ PDF Chat	Adaptive dose finding based ont-statistic for dose–response trials	2008	Anastasia Ivanova James A. Bolognese Inna Perevozskaya
+ PDF Chat	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist	2008	Sarah Zohar Lian Qing Vincent Lévy Kmc Cheung Anastasia Ivanova Sylvie Chevret
+	Phase <scp>I</scp> Trials in Oncology	2007	Anastasia Ivanova
+	Dose Escalation and Up‐and‐Down Designs	2007	Anastasia Ivanova
+	Dose-finding trials in oncology	2007	Anastasia Ivanova
+	Efficient generation of constrained block allocation sequences	2007	Ibrahim Salama Anastasia Ivanova Bahjat F. Qaqish
+	Phase I Clinical Trials	2007	Anastasia Ivanova Nancy Flournoy
+	Dose-Finding in Oncology—Nonparametric Methods	2006	Anastasia Ivanova
+	Multivariate logistic models	2006	Bahjat F. Qaqish Anastasia Ivanova
+	Cumulative cohort design for dose-finding	2006	Anastasia Ivanova Nancy Flournoy Yeonseung Chung
+	Escalation, group andA +B designs for dose-finding trials	2005	Anastasia Ivanova
+	Bivariate isotonic design for dose‐finding with ordered groups	2005	Anastasia Ivanova Kai Wang
+	Urn designs with immigration: Useful connection with continuous time stochastic processes	2005	Anastasia Ivanova
+	Response-adaptive designs for continuous outcomes	2005	Anastasia Ivanova Atanu Biswas Anna Lurie
+	Continuous Toxicity Monitoring in Phase II Trials in Oncology	2005	Anastasia Ivanova Bahjat F. Qaqish Michael J. Schell
+	Two‐Dimensional Dose Finding in Discrete Dose Space	2005	Kai Wang Anastasia Ivanova
+	Adjusting for observable selection bias in block randomized trials	2005	Anastasia Ivanova Robert Barrier Vance W. Berger
+	The use of the triangular test with response‐adaptive treatment allocation	2005	D. Stephen Coad Anastasia Ivanova
+	Sequential urn designs with elimination for comparingK3 treatments	2005	D. Stephen Coad Anastasia Ivanova
+	A non‐parametric approach to the design and analysis of two‐dimensional dose‐finding trials	2004	Anastasia Ivanova Kai Wang
+	Adjusting for Ordinal Covariates by Inducing a Partial Ordering	2004	Vance W. Berger YanYan Zhou Anastasia Ivanova Lothar Tremmel
+	A New Dose‐Finding Design for Bivariate Outcomes	2003	Anastasia Ivanova
+	Minimizing predictability while retaining balance through the use of less restrictive randomization procedures	2003	Vance W. Berger Anastasia Ivanova Maria Deloria Knoll
+	A play-the-winner-type urn design with reduced variability	2003	Anastasia Ivanova
+	Improved up‐and‐down designs for phase I trials	2002	Anastasia Ivanova A. Montazer-Haghighi Sri Gopal Mohanty S. D. Durham
+ PDF Chat	Adaptive Tests for Ordered Categorical Data	2002	Vance W. Berger Anastasia Ivanova
+	The bias of linear rank tests when testing for stochastic order in ordered categorical data	2002	Vance W. Berger Anastasia Ivanova
+	Adaptive Designs for Clinical Trials with Highly Successful Treatments	2001	Anastasia Ivanova William F. Rosenberger
+	Optimal Adaptive Designs for Binary Response Trials	2001	William F. Rosenberger Nigel Stallard Anastasia Ivanova Cherice N. Harper Michelle L. Ricks
+	BIAS CALCULATIONS FOR ADAPTIVE URN DESIGNS	2001	D. Stephen Coad Anastasia Ivanova
+ PDF Chat	Drawbacks to Integer Scoring for Ordered Categorical Data	2001	Anastasia Ivanova Vance W. Berger
+	Permutation Tests for Phase III Clinical Trials	2001	Vance W. Berger Anastasia Ivanova
+	A COMPARISON OF URN DESIGNS FOR RANDOMIZED CLINICAL TRIALS OF <i>K</i> > 2 TREATMENTS	2000	Anastasia Ivanova William F. Rosenberger
+	Convex Hull Test for Ordered Categorical Data	1998	Vance W. Berger Thomas Permutt Anastasia Ivanova

Common Coauthors

Coauthor	Papers Together
Jason P. Fine	11
Olga Marchenko	9
Vance W. Berger	8
Bahjat F. Qaqish	5
Inna Perevozskaya	5
Changfu Xiao	5
Guochen Song	5
Nancy Flournoy	4
William F. Rosenberger	4
Gary L. Rosner	4
Lisa M. LaVange	4
Rachel Kloss Silverman	4
James N. Moy	3
Wendy C. Moore	3
W. Gerald Teague	3
Rajesh Kumar	3
David T. Mauger	3
Mark C. Liu	3
Yuan Ji	3
Sally E. Wenzel	3
Lewis J. Smith	3
Jerry A. Krishnan	3
Matthew C. Foster	3
Steven Hoberman	3
Rosalind J. Wright	3
Michael R. Kosorok	3
Sonia Jain	3
John V. Fahy	3
Lang Li	3
Kristie Ross	3
Benjamin Gaston	3
Fernando Holguín	3
Praveen Akuthota	3
Leonard B. Bacharier	3
Serpil C. Erzurum	3
Tom Parke	3
Yunro Chung	3
Patricia Noël	3
Kai Wang	3
Loren C. Denlinger	3
Wanda Phipatanakul	3
Stanley J. Szefler	3
Mario Castro	3
Michael E. Wechsler	3
Merritt L. Fajt	3
Ngoc P. Ly	3
Juan Carlos Cardet	3
Elliot Israel	3
Emily DiMango	3
Miriam Marquis	3

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	25
+	Improved up‐and‐down designs for phase I trials	2002	Anastasia Ivanova A. Montazer-Haghighi Sri Gopal Mohanty S. D. Durham	18
+	Cumulative cohort design for dose-finding	2006	Anastasia Ivanova Nancy Flournoy Yeonseung Chung	16
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer	15
+	Escalation, group andA +B designs for dose-finding trials	2005	Anastasia Ivanova	15
+	A comparison of two phase I trial designs	1994	Edward L. Korn Douglas Midthune T. Timothy Chen Larry Rubinstein Michaele C. Christian Richard Simon	14
+ PDF Chat	Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities	2000	Ying Kuen Cheung Rick Chappell	13
+	Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials	2001	Yong Lin Weichung Joe Shih	12
+	Random Walks for Quantile Estimation	1994	S. D. Durham Nancy Flournoy	12
+	The Randomized Play-the-Winner Rule in Medical Trials	1978	L. J. Wei S. D. Durham	11
+	Dose Finding Using the Biased Coin Up‐and‐Down Design and Isotonic Regression	2002	Mario Stylianou Nancy Flournoy	11
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks	11
+ PDF Chat	Up-and-down designs. I. Stationary treatment distributions	1995	S. D. Durham Nancy Flournoy	10
+	Optimality, sample size, and power calculations for the sequential parallel comparison design	2011	Anastasia Ivanova Bahjat F. Qaqish David Schoenfeld	10
+	Dose‐Finding with Two Agents in Phase I Oncology Trials	2003	Peter F. Thall Randall E. Millikan Peter P. Mueller Sang Joon Lee	10
+	Comparison of Test Statistics for the Sequential Parallel Design	2010	Xiaohong Huang Roy Tamura	10
+	Operating characteristics of the standard phase I clinical trial design	1999	Ethan Reiner Xavier Paolettí John O’Quigley	10
+	Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials	2011	Yeh‐Fong Chen Yang Yang Hung Hung Sue‐Jane Wang	9
+	Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial	2004	B. Nebiyou Bekele Peter F. Thall	9
+ PDF Chat	Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach	2008	Anastasia Ivanova Se Hee Kim	9
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	8
+ PDF Chat	Coherence principles in dose-finding studies	2005	Ying Kuen Cheung	8
+	Two‐Dimensional Dose Finding in Discrete Dose Space	2005	Kai Wang Anastasia Ivanova	8
+	Group sequential methods in the design and analysis of clinical trials	1977	Stuart J. Pocock	7
+ PDF Chat	The Generalized Polya's Urn Design for Sequential Medical Trials	1979	L. J. Wei	7
+	A play-the-winner-type urn design with reduced variability	2003	Anastasia Ivanova	7
+	Group Sequential Methods with Applications to Clinical Trials	1999	Christopher Jennison Bruce W. Turnbull	7
+	A sequential design for maximizing the probability of a favourable response	1998	S. D. Durham Nancy Flournoy W. Li	7
+	Dose Finding by the Continual Reassessment Method	2011	Ying Kuen Cheung	6
+ PDF Chat	Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?	1994	Madhukar H. Trivedi A. John Rush	6
+	A New Dose‐Finding Design for Bivariate Outcomes	2003	Anastasia Ivanova	6
+	Adaptive Designs for Clinical Trials with Highly Successful Treatments	2001	Anastasia Ivanova William F. Rosenberger	6
+	Continual Reassessment Method for Ordered Groups	2003	John O’Quigley Xavier Paolettí	6
+	Dose Finding in Drug Development	2006	Naitee Ting	6
+	The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach	2006	Zheng Yuan Rick Chappell Howard H. Bailey	6
+ PDF Chat	Variability in Adaptive Designs for Estimation of Success Probabilities	1998	Vincent Melfi Connie Page	6
+	Random Walk Design in Bio-Assay	1967	Robert K. Tsutakawa	6
+	Statistical Methods for Dose‐Finding Experiments	2006		6
+	An examination of the efficiency of the sequential parallel design in psychiatric clinical trials	2007	Roy Tamura Xiaohong Huang	6
+	When should the sequential parallel comparison design be used in clinical trials?	2013	Lee Baer Anastasia Ivanova	6
+	Designs for Single‐ or Multiple‐Agent Phase I Trials	2004	Mark R. Conaway Stephanie Dunbar Shyamal D. Peddada	6
+	Competing designs for phase I clinical trials: a review	2002	William F. Rosenberger Linda M. Haines	6
+	Group up-and-down designs for dose-finding	2005	Misrak Gezmu Nancy Flournoy	6
+	The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design	2001	Seung-Ho Kang Chul Ahn	6
+	Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs	1997	William F. Rosenberger Nancy Flournoy S. D. Durham	6
+	Bivariate isotonic design for dose‐finding with ordered groups	2005	Anastasia Ivanova Kai Wang	6
+	A COMPARISON OF URN DESIGNS FOR RANDOMIZED CLINICAL TRIALS OF <i>K</i> > 2 TREATMENTS	2000	Anastasia Ivanova William F. Rosenberger	5
+	Continuous Toxicity Monitoring in Phase II Trials in Oncology	2005	Anastasia Ivanova Bahjat F. Qaqish Michael J. Schell	5
+	The doubly adaptive biased coin design for sequential clinical trials	1994	Jeffrey R. Eisele	5
+ PDF Chat	A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies	2013	Gheorghe Doros Michael Pencina Denis Rybin Allison Meisner Maurizio Fava	5